Physician profile
Rick D Watson
NPI 1649228537
$1,051.72
in general payments reported to CMS, 2019-2025
23 companies · $381 in 2025
The $381 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $78.22 · 2021: $2.50 · 2022: $52.03 · 2023: $173 · 2024: $111 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $665.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $222.81 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $128.38 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Ars Pharmaceuticals Operations, INC. | $103.15 | 2025 | Neffy |
| Dexcom, INC. | $95.00 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Regeneron Healthcare Solutions, INC. | $67.22 | 2019-2023 | Dupixent |
| Novo Nordisk INC | $63.14 | 2019-2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.11 | 2019-2023 | |
| Corcept Therapeutics | $48.39 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.40 | 2023 | Reblozyl |
| Genzyme Corporation | $30.92 | 2025 | |
| Verona Pharma, INC. | $22.50 | 2025 | Ohtuvayre |
| Inogen, INC. | $22.11 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Amgen INC. | $19.25 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.09 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $15.79 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $14.88 | 2022 | |
| Tandem Diabetes Care, INC. | $14.75 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.53 | 2024 | Glassia |
| Abbvie INC. | $13.26 | 2023 | Ubrelvy |
| Pfizer INC. | $13.09 | 2023 | |
| Shire North American Group INC | $11.92 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.53 | 2019 | |
| United Therapeutics Corporation | $2.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rick Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.